What question did this study set out to answer?

This review explores current management strategies for HBV-related hepatocellular carcinoma and identifies future research directions.

June 17, 2026Gastroenterology reportOpen Access

Current advances and future directions in the management of HBV-related hepatocellular carcinoma

View Full Paper

Ask AI

Bookmark

This review explores current management strategies for HBV-related hepatocellular carcinoma and identifies future research directions.
Synthesized findings from various studies on HBV-related HCC treatments and surveillance strategies.
Discussed molecular pathogenesis, risk stratification tools, antiviral strategies, and immunotherapy options.
Highlighted special clinical considerations such as high viral load and tumor thrombus.
Nucleos(t)ide analog therapy was effective in reducing HBV replication but residual HCC risk remains.
Immune checkpoint inhibitor-based combinations established as first-line options for unresectable HCC.
Emerging roles for ICIs in earlier disease settings and combinations with locoregional therapies were suggested.

No takes yet. Share an insight, caveat, or question.

This review highlights recent advances in managing HBV-related hepatocellular carcinoma, emphasizing treatment strategies and safety considerations.

Ibrahim et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

This review highlights recent advances in managing HBV-related hepatocellular carcinoma, emphasizing treatment strategies and safety considerations.